Diane Harper

Last updated

Diane M. Harper
Diane Harper HS.png
Alma materMassachusetts Institute of Technology (BS 1980; MS 1982); University of Kansas School of Medicine (MD 1986; MPH 1995)
Known forInvestigations in HPV vaccine trials; contributions to screening and policy; self-sampling to replace the speculum exam for cervical cancer screening
Awards
  • EuroGin Distinguished Service Award for Cancer Prevention (2006)
  • Prix Monte-Carlo Femme de l’Année (2013)
  • Society of Teachers of Family Medicine Excellence in Education Award (2013)
  • Curtis G. Hames Lifetime Award for Research (2015)
  • Notre Dame de Sion Outstanding Alumna (2015)
  • Association of American Physicians (elected 2023)
Scientific career
FieldsWomen's health care; cervical cancer prevention continuum; virology; vaccine development; cancer prevention
InstitutionsDartmouth Medical School (1996–2009); University of Missouri–Kansas City (2009–2013); University of Louisville (2013–2017); University of Michigan (2018–present)

Diane M. Harper is an American physician-scientist and tenured professor of Family Medicine, Obstetrics and Gynecology, Bioengineering, and Women's and Gender Studies at the University of Michigan. Her research focuses on human papillomavirus (HPV), cervical cancer prevention, screening methods, and clinical decision-making. She was a site and study investigator in multicenter clinical trials of prophylactic HPV vaccines. Harper has also co-authored studies on therapeutic HPV vaccines, self-sampling for screening, and vaginal microbiome interventions.

Contents

Harper's academic appointments include Dartmouth Medical School (clerkship director, residency director, LCME team, Director of the Gynecologic Cancer Prevention Clinics), the University of Missouri–Kansas City (research director, LCME team), the University of Louisville (department chair, LCME team), and the University of Michigan (LCME team; senior associate director, Michigan Institute for Clinical and Healthcare Research). She has served as a member of the U.S. Preventive Services Task Force and as physician director for Community Outreach, Engagement and Health Disparities at the Rogel Cancer Center. [1] [2] [3] [4] [5] [6] [7] [8]

Early life and education

Harper graduated valedictorian from Notre Dame de Sion High School in Kansas City, Missouri. She earned a B.S. in Chemical Engineering from the Massachusetts Institute of Technology in 1980 and an M.S. in 1982, then completed the M.D. (1986) and M.P.H. in Biostatistics & Epidemiology (1995) at the University of Kansas School of Medicine. [2] [9]

Career

Harper has spent her career at the following institutions: Dartmouth Medical School (1996–2009); University of Missouri–Kansas City (2009–2013); University of Louisville, chair of Family & Geriatric Medicine (2013–2017); and University of Michigan (2018–present). She was appointed to the U.S. Preventive Services Task Force in 2016 and joined the U-M Institute for Healthcare Policy & Innovation and the Rogel Cancer Center in 2018. [2] [4] [5] [6] [7]

Research and contributions

Harper served as a U.S. investigator in multicenter clinical trials for Cervarix (bivalent L1 virus-like particle HPV vaccine, types 16/18) and Gardasil (quadrivalent L1 virus-like particle HPV vaccine, types 6/11/16/18). In a 2004 Lancet trial, Harper and co-authors reported efficacy against persistent HPV-16/18 infection; a 2006 Lancet follow-up reported sustained efficacy through 4.5 years. [10] [11] In 2007, Harper co-authored a New England Journal of Medicine article reporting quadrivalent vaccine outcomes and contributed to a Bulletin of the World Health Organization review on HPV vaccines. [12] [13] A combined Lancet analysis that year reported efficacy against high-grade vulvar and vaginal HPV-associated lesions. [14]

In 2017, Harper and Leslie DeMars published a review of the first decade of HPV vaccination in Gynecologic Oncology , summarizing trial results and implementation considerations. [15]

In 2019, Harper co-authored a randomized, controlled phase II trial evaluating the therapeutic HPV vaccine tipapkinogen sovacivec for CIN2/3 with 2.5-year follow-up, reporting efficacy and safety outcomes in Gynecologic Oncology. [16]

In 2025, Harper and collaborators reported U.S. studies on self-collected versus clinician-collected samples for HPV detection and genotyping in Preventive Medicine Reports and Cancer Epidemiology, Biomarkers & Prevention ; media coverage summarized these findings for general audiences. [17] [18] [19] In parallel, Harper co-authored a study of screening among women with physical disabilities that described barriers associated with speculum-based exams and reported acceptability of at-home self-sampling. [20] Harper also co-authored a randomized, placebo-controlled trial in npj Biofilms and Microbiomes assessing a multi-strain Lactobacillus crispatus –based synbiotic and its effects on the vaginal microbiome. [21]

Materials from the Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices and the World Health Organization provide context for vaccination and screening recommendations that relate to these studies. [22] [23] [24]

Media outlets have reported on Harper’s studies and on discussions of HPV vaccination, duration of protection, and post-vaccination screening; coverage has also noted her appearances at an National Vaccine Information Center-hosted event and in the film The Greater Good . [25] [26] [27] [28] [29]

Awards and honors

Selected publications

References

  1. ↑ Medved, Diane Lynn (1980). The fabrication and characterization of polyester and vinyl ester sheet molding compounds (Thesis). Massachusetts Institute of Technology.
  2. 1 2 3 Durgin, Jennifer (2006). "Dream Work: Diane Harper, M.D., M.P.H." Dartmouth Medicine Magazine. Retrieved October 16, 2025.
  3. ↑ "Diane Harper: HPV, cervical cancer screening, and balancing benefits and harms". ihpi.umich.edu. U-M Institute for Healthcare Policy & Innovation. December 12, 2018. Retrieved October 16, 2025.
  4. 1 2 "Appointment of Four New U.S. Preventive Services Task Force Members". United States Preventive Services Taskforce. February 2016. Retrieved October 16, 2025.
  5. 1 2 3 "2013 - FEMME DE L'ANNEE". prixmontecarlofda.com. Archived from the original on April 12, 2017. Retrieved October 16, 2025.
  6. 1 2 3 "Diane M. Harper". medschool.umich.edu. Michigan Medicine. Archived from the original on August 13, 2025. Retrieved October 16, 2025.
  7. 1 2 "HPV specialist Diane Harper to lead community outreach efforts at the Cancer Center". Rogel Cancer Center. March 27, 2018. Archived from the original on June 9, 2024. Retrieved October 16, 2025.
  8. ↑ "Harper elected to the Association of American Physicians". ihpi.umich.edu. U-M Institute for Healthcare Policy & Innovation. April 26, 2023. Retrieved October 16, 2025.
  9. ↑ "Diane M. Harper, M.D., M.P.H., M.S." ihpi.umich.edu. U-M Institute for Healthcare Policy & Innovation. Retrieved October 16, 2025.
  10. 1 2 Harper, Diane M.; Franco, Eduardo L.; Wheeler, Cosette; Ferris, Daron G.; Jenkins, David; Schuind, Anne; Zahaf, Toufik; Innis, Bruce; Naud, Paulo; de Carvalho, Newton S.; Roteli-Martins, Cecilia M.; Teixeira, Julio; Blatter, Mark M.; Korn, Abner P.; Quint, Wim (2004). "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial". The Lancet. 364 (9447): 1757–1765. doi:10.1016/S0140-6736(04)17398-4. PMID   15541448.
  11. 1 2 Harper, D. M.; Franco, E. L.; Wheeler, C. M.; Moscicki, A. B.; Romanowski, B.; Roteli-Martins, C. M.; Jenkins, D.; Schuind, A.; Costa Clemens, S. A.; Dubin, G.; HPV Vaccine Study group (2006). "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial". The Lancet. 367 (9518): 1247–1255. doi:10.1016/S0140-6736(06)68439-0. PMID   16631880.
  12. ↑ Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (May 10, 2007). "Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases". The New England Journal of Medicine. 356 (19): 1928–1943. doi:10.1056/NEJMoa061760. PMID 17494926.
  13. ↑ Cutts FT, Franceschi S, Goldie S, Castellsagué X, Harper DM, et al. (September 2007). "Human papillomavirus and HPV vaccines: a review". Bulletin of the World Health Organization. 85 (9): 719–726. doi:10.2471/blt.06.038414. PMID 18026629. PMCID PMC2636411.
  14. ↑ Joura, E. A.; Leodolter, S.; Hernandez-Avila, M.; Wheeler, C. M.; Perez, G.; Koutsky, L. A.; Garland, S. M.; Harper, D. M.; Tang, G. W.; Ferris, D. G.; Steben, M.; Jones, R. W.; Bryan, J.; Taddeo, F. J.; Bautista, O. M. (2007). "Efficacy of a quadrivalent prophylactic human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials". The Lancet. 369 (9574): 1693–2302. doi:10.1016/S0140-6736(07)60777-6. PMID   17512854.
  15. 1 2 Harper, D. M.; Demars, L. R. (2017). "HPV vaccines - A review of the first decade". Gynecologic Oncology. 146 (1): 196–204. doi:10.1016/j.ygyno.2017.04.004. PMID   28442134.
  16. 1 2 Harper, D. M.; Nieminen, P.; Donders, G.; Einstein, M. H.; Garcia, F.; Huh, W. K.; Stoler, M. H.; Glavini, K.; Attley, G.; Limacher, J. M.; Bastien, B.; Calleja, E. (2019). "The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up". Gynecologic Oncology. 153 (3): 521–529. doi:10.1016/j.ygyno.2019.03.250. PMID   30955915.
  17. 1 2 Young, A. P.; Olorunfemi, M.; Morrison, L.; Kelley, S. A.; Laurie, A.; McEvoy, A.; Schneiderhan, J.; Prussack, J.; O'Dwyer, M. C.; Rockwell, P.; Zazove, P.; Gabison, J.; Chargot, J.; Gallagher, K.; Sen, A.; Chen, D.; Haro, E. A.; Butcher, E. A.; Alves, M. L.; El Khoury, C.; Dendrinos, M. L.; Brashear, N.; Smith, R.; Lieberman, R. W.; Saunders, N.; Campbell, E.; Walline, H. M.; Harper, D. M. (2025). "Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping". Preventive Medicine Reports. 50. doi:10.1016/j.pmedr.2025.102971. PMC   11791345 . PMID   39906308.
  18. 1 2 Harper, D. M.; Young, A. P.; O'Dwyer, M. C.; Olorunfemi, M.; Laurie, A.; Sen, A.; Chen, D.; Morrison, L.; Kelley, S. A.; McEvoy, A.; Schneiderhan, J.; Rockwell, P.; Zazove, P.; Gabison, J.; Chargot, J. E.; Gallagher, K.; Prussack, J.; Butcher, E. A.; Alves, M. L.; Haro, E. A.; El Khoury, C.; Smith, R.; Saunders, N.; Campbell, E.; Walline, H. M. (2025). "Comparison of Human Papillomavirus Genotyping by Research vs. Clinical Assay for Two Self-Collection Devices". Cancer Epidemiology, Biomarkers & Prevention. 34 (7): 1103–1110. doi:10.1158/1055-9965.EPI-25-0116. PMC  12213154. PMID   40279251.
  19. ↑ Lapid, Nancy (February 21, 2025). "Health Rounds: Swabs as good as unpleasant speculum exam for detecting cancer-causing HPV". Reuters. Retrieved October 16, 2025.
  20. ↑ Vinson, A. H.; Norrid, C.; Haro, E. K.; Ernst, S.; El Khoury, C.; Alves, M. L.; Kieber-Emmons, A.; Kamath Mulki, A.; Butcher, E. A.; Kalpakjian, C.; McKee, M. M.; Harper, D. M. (2025). "Cervical Cancer Screening in Women with Physical Disabilities". JAMA Network Open. 8 (1): e2457290. doi:10.1001/jamanetworkopen.2024.57290. PMC   11780472 . PMID   39878976.
  21. 1 2 Ravel, J.; Simmons, S.; Jaswa, E. G.; Gottfried, S.; Greene, M.; Kellogg-Spadt, S.; Gevers, D.; Harper, D. M. (2025). "Impact of a multi-strain L. Crispatus-based vaginal synbiotic on the vaginal microbiome: A randomized placebo-controlled trial". npj Biofilms and Microbiomes. 11 (1): 158. doi:10.1038/s41522-025-00788-6. PMC   12335476 . PMID   40783570.
  22. ↑ "HPV Vaccination Recommendations". Centers for Disease Control and Prevention. September 23, 2025. Retrieved October 17, 2025.
  23. ↑ "Human papillomavirus vaccines: WHO position paper, December 2022". Weekly Epidemiological Record. 97 (50): 645–672. December 16, 2022.
  24. ↑ "Global strategy to accelerate the elimination of cervical cancer as a public health problem". World Health Organization. November 17, 2020. Retrieved October 17, 2025.
  25. ↑ Goldacre, Ben (October 9, 2009). "Cancer jab fantasy closes down a debate". The Guardian. ISSN   0261-3077 . Retrieved October 17, 2025.
  26. 1 2 "ROYAL MONACO N°8 SPECIALE CANNES '13". Royal Monaco. Archived from the original on January 24, 2025. Retrieved October 16, 2025.
  27. 1 2 Burnett, Rosemary J. (April 2014). "The South African human papillomavirus vaccination programme for grade 4 girls: facts and fallacies" (PDF). SAVIC. Retrieved October 16, 2025.
  28. ↑ Anderson, John (October 16, 2011). "The Greater Good". Variety. Retrieved October 17, 2025.
  29. ↑ Specter, Michael (2009). Denialism: How Irrational Thinking Hinders Scientific Progress and Harms the Planet. New York: Penguin Press. p. 7. ISBN 9781594202308.
  30. ↑ "Geisel/DMS Roundup". geiselmed.dartmouth.edu. Archived from the original on January 9, 2023. Retrieved October 16, 2025.
  31. ↑ "Past Award Winners – STFM Excellence in Education Award". Society of Teachers of Family Medicine. Retrieved October 18, 2025.
  32. ↑ "STFM Annual Spring Conference Program (2013)" (PDF). Society of Teachers of Family Medicine. Retrieved October 18, 2025.
  33. ↑ "Outstanding Alumnae". Notre Dame de Sion School For Girls. Retrieved October 16, 2025.
  34. ↑ "Family Medicine's Diane Harper elected to the Association of American Physicians". Rogel Cancer Center. April 27, 2023. Archived from the original on June 6, 2024. Retrieved October 17, 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.